Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Active, not recruitingOBSERVATIONAL
Enrollment
26,000
Participants
Timeline
Start Date
January 1, 2025
Primary Completion Date
June 1, 2025
Study Completion Date
September 1, 2025
Conditions
Type 2 DiabetesHeart Failure
Interventions
DRUG
Tirzepatide
Exposure group
DRUG
Semaglutide
Referent group
Trial Locations (1)
02120
Brigham and Women's Hospital, Boston
All Listed Sponsors
lead
Brigham and Women's Hospital
OTHER
NCT06980623 - Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter